OCV 501

Drug Profile

OCV 501

Alternative Names: OCV501; WT1-targeted-cancer-vaccine-Otsuka

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator International Institute of Cancer Immunology
  • Developer Otsuka Pharmaceutical
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 06 Sep 2017 Phase-II clinical development is ongoing in Japan, South Korea and Taiwan (NCT01961882)
  • 06 Dec 2016 Safety and efficacy results from a phase I trial in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 22 Feb 2016 Otsuka completes enrolment in a phase II trial for Acute myeloid leukaemia (In the elderly, Prevention of relapse) in Japan, South Korea and Taiwan (NCT01961882)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top